依达拉奉对脑缺血再灌注后A&beta;及其前体表达干预

任海燕; 赵晖; 王蕾; 许晨波; 马梅蕾; 文娟

doi:10.3981/j.issn.1000-7857.2015.12.013

科技导报 >

2015 , Vol. 33 >Issue 12: 77 - 82

DOI: https://doi.org/10.3981/j.issn.1000-7857.2015.12.013

研究论文

依达拉奉对脑缺血再灌注后Aβ及其前体表达干预

任海燕 ,
赵晖 ,
王蕾 ,
许晨波 ,
马梅蕾 ,
文娟

展开

1. 新疆医科大学基础医学院, 乌鲁木齐830054;
2. 首都医科大学中医药学院, 北京100054;
3. 日本新潟药科大学临床药理学实验室, 东京956-8603

任海燕, 主治医师, 研究方向为神经病理生理学, 电子信箱:424732833@qq.com

收稿日期: 2015-01-14

修回日期: 2015-04-21

网络出版日期: 2015-07-15

基金资助

新疆维吾尔自治区自然科学基金项目(2011211A046)

收起

Intervention of Edaravone on expression of β amyloid and amyloid precursor protein after cerebral ischemia reperfusion

REN Haiyan ,
ZHAO Hui ,
WANG Lei ,
XU Chenbo ,
MA Meilei ,
WEN Juan

Expand

1. School of Basic Medicine, Xinjiang Medical University, Urumqi 830054, China;
2. School of Traditional Chinese Medicine, Capital Medical University, Beijing 100054, China;
3. Laboratory of Clinical Pharmacology, Nigata University of Pharmacy and Applied Life Sciences, Tokyo 956-8603, Japan

Received date: 2015-01-14

Revised date: 2015-04-21

Online published: 2015-07-15

Fold

摘要

为探讨缺血再灌注对大鼠海马区神经元细胞的损伤机制及依达拉奉的干预作用, 利用大脑中动脉线栓法制备大鼠脑缺血再灌模型, 缺血2 h 后再灌注22 h(术后24 h), 按照Zea Longa 5 级评分法, 对大鼠进行神经行为学评分;通过苏木精-伊红染色法(HE)染色大鼠脑组织, 观察其病理形态学的改变;通过免疫组织化学, 图像分析及Western Blot 的方法检测大鼠海马区β淀粉样蛋白(Aβ)及其前体(APP)的表达。结果显示, 模型组大鼠表现出明显的神经功能缺损症状, 与之相比, 6 和10 mg/kg 的依达拉奉可不同程度改善损伤模型大鼠的神经缺损症状, 尤其是10 mg/kg 依达拉奉组的大鼠症状改善更为明显(P<0.01);HE 染色结果显示, 模型组大鼠海马区神经元细胞脱失明显, 而治疗组可减轻这种形态学改变;免疫组织化学及Western Blot 分析结果提示, 在模型组中Aβ、APP 表达明显高于假手术组(P<0.01), 而在不同质量分数依达拉奉组中, Aβ、APP 含量均减弱(P<0.05)。由此得出, 缺血再灌注可能通过上调淀粉样蛋白Aβ及其前体APP 而引起神经元细胞损伤, 而依达拉奉可能通过对它们的抑制起到保护神经元细胞的作用。

关键词： 脑缺血再灌注; β淀粉样蛋白; 淀粉样蛋白前体; 依达拉奉; 脑缺血再灌注; β 淀粉样蛋白; 淀粉样蛋白前体; 依达拉奉

本文引用格式

任海燕 , 赵晖 , 王蕾 , 许晨波 , 马梅蕾 , 文娟 . 依达拉奉对脑缺血再灌注后Aβ及其前体表达干预[J]. 科技导报, 2015 , 33(12) : 77 -82 . DOI: 10.3981/j.issn.1000-7857.2015.12.013

Abstract

This paper investigates the damage mechanism of rat hippocampal neurons induced by the ischemia reperfusion and the intervention of the Edaravone. An ischemia reperfusion model is built by the middle cerebral artery occlusion (MACO)-reperfusion method. The reperfusion is performed 2 hours after the ischemia and persists for 22 hours (24 h since surgery). According to the Zea Longa's 5 level evaluation method, the neurobehavioral score of rats is graded; The rats' tissue pathological morphological changes are observed by the HE staining; the expressions of amyloid β (Aβ) and its precursor (APP) in the hippocampus of rats are detected with the immunohistochemistry, the image analysis and the Western Blot. It is shown that the model group rats show obvious symptoms of the nerve function defect; By contrast, the Edaravone of 6 and 10 mg/kg could improve model rats' symptoms of the nerve defect in varying degrees; And the difference is more significant in 10 mg/kg group (P<0.01). The HE staining shows that the depigmentation of the model group rat hippocampal neurons is obvious, and the two treatment groups could reduce this kind of morphology change; The immunohistochemistry and Western Blot analysis results suggest that both levels of Aβ and APP in the model group are significantly higher than those in the sham group (P<0.01), however, in different concentrations of Edaravone groups, their expression is significantly reduced (P<0.05). It is concluded that the ischemia reperfusion could cause neuron cells' damage by increasing Aβ and APP, and the Edaravone might suppress their toxic effects and protect the neuron cells by decreasing their expression.

Key words： cerebral ischemia reperfusion; β amyloid; amyloid precursor protein; Edaravone; cerebral ischemia reperfusion; β amyloid; amyloid precursor protein; Edaravone

参考文献

[1] Manley G T, Binder D K, Papadopoulos M C, et al. New insights into water transport and edema in the central nervous system from phenotype analysis of aquaporin- 4 null mice[J]. Neuroscience, 2004, 129: 983-991.
[2] Hardy J A, Higgins G A. Alzheimer's disease: The amyloid cascade hypothesis[J]. Science, 1992, 25(6): 184-185.
[3] Jendroska K, Hoffmann O M, Patt S. Amyloid beta peptide and precursor protein (APP) in mild and severe brain ischemia[J]. Annals of the New York Academy of Sciences, 1997, 826: 401-405.
[4] Kalaria R N. The role of cerebral ischemia in Alzheimer's disease[J]. Neurobiol Aging, 2000, 21(2): 321-330.
[5] 闫福玲. 重视Alzheimer病与脑缺血的共病研究[J]. 国际脑血管病杂志, 2006, 14(11): 801-802. Yan Fuling. Attaching importance to comorbidity study of Alzheimer's disease and cerebral ischemia[J]. International Journal of Cerebrovascular Diseases, 2006, 14(11): 801-802.
[6] Hardy J, Selkoe D J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics[J]. Science, 2002, 297(5580): 353-356.
[7] Woltjer R L, McMahan W, Milatovic D, et al. Effects of chemical chaperones on oxidative stress and detergent-insoluble species formation following conditional expression of amyloid precursor protein carboxyterminal fragment[J]. Neurobiology of Disease, 2007, 25(2): 427-437.
[8] Tillement L, Lecanu L, Papadopoulos V. Alzheimer's disease: Effects of beta-amyloid on mitochondria[J]. Mitochondrion, 2011, 11(1): 13-21.
[9] Cardoso S M, Proenca M T, Santos S, et al. Cytochrome c oxidase is decreased in Alzheimer's disease platelets[J]. Neurobiology of Aging, 2004, 25(1): 105-110.
[10] Gibson G E, Blass J P, Beal M F, et al. The alphaketoglutaratedehydrogenase complex: A mediator between mitochondria and oxidative stress in neurodegeneration[J]. Molecular Neurobiology, 2005, 31(1-3): 43-63.
[11] Pickrell A M, Fukui H, Moraes C T. The role of cytochrome c oxidase deficiency in ROS and amyloid plaque formation[J]. Journal of Bioenergetics and Biomembranes, 2009, 41(5): 453-456.
[12] Tauskela J S. MitoQ-a mitochondria-targeted antioxidant[J]. IDrugs, 2007, 10(6): 399-412.
[13] Spindler M, Beal M F, Henchcliffe C. Coenzyme Q10 effects in neurodegenerative disease[J]. Neuropsychiatric Disease and Treatment, 2009, 5: 597-610.
[14] Shen Y E, Wang Y, Yu G C, et al. Effects of edaravone on amyloid-β precursor protein processing in SY5Y- APP695 cells[J]. Neurotoxicity Research, 2013, 24: 139-147.
[15] Taupin P. A dual activity of ROS and oxidative stress on adult neurogenesis and Alzheimer's disease[J]. Central Nervous System Agents in Medicinal Chemistry, 2010, 10(1): 16-21.
[16] Green A R, Shuaib A. Therapeutic strategies for the treatment of stroke [J]. Drug Discovery Today, 2006, 11: 681-693.
[17] van der Worp H B, Kappelle L J, Algra A, et al. The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke[J]. Neurology, 2002, 58: 133-135.
[18] Cuzzocrea S, Costantino G, Gitto E, et al. Protective effects of melatonin in ischemic brain injury[J]. Journal of Pineal Research, 2000, 29: 217-227.
[19] 王海征, 张秋霞, 赵晖, 等. 风药、补虚药对脑缺血大鼠淀粉样β蛋白及其蛋白前体表达的影响[J]. 世界中医药, 2013, 8(8): 942-945. Wang Haizheng, Zhang Qiuxia, Zhao Hui, et al. Influence of winddispelling medicine assisted with deficiency-nourishing medicine on the expression of APP and Aβ42 for cerebral ischemic in rats model [J]. World Chinese Medicine, 2013, 8(8): 942-945.
[20] 李泰东, 陆国辉, 崔云燕, 等. 缺血再灌注对大鼠海马神经元淀粉样蛋白及其蛋白前体表达的影响及人参皂甙Rg2的干预[J]. 中风与神经疾病杂志, 2008(4): 417-420. Li Taidong, Lu Guohui, Cui Yunyan, et al. Effects of ischemia reperfusion on expression of amyloid and amyloid precursor protein in rat hippocampal neurons and the intervention of ginsenoside Rg2[J]. Journal of Apoplexy and Nervous Diseases, 2008(4): 417-420.
[21] Longa E Z, Weinstein P R, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in Rats[J]. Stroke, 1989, 20(1): 84-91.
[22] 韩晶, 冯加纯. 脑缺血损伤后β淀粉样蛋白及其前体蛋白在脑组织中的表达及治疗[J]. 实用心脑肺血管病杂志, 2006, 14(12): 935-937. Han Jing, Feng Jiachun. Expression and treatment of β amyloid and its precursor protein in the brain after cerebral ischemia reperfusion injury[J]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease, 2006, 14(12): 935-937.
[23] Selkoe D J. Alzheimer's disease: Genes, proteins, and therapy[J]. Physiological Reviews, 2001, 81(2): 741-766.
[24] Reiss A B. Cholesterol and apolipoprotein E in Alzheimer's disease[J]. American Journal of Alzheimer's Disease & Other Dementias, 2005, 20(2): 91-96.
[25] 苏心, 张文治, 吴剑娟. β淀粉样蛋白对培养胎鼠大脑神经干细胞作用的研究[J]. 中华老年心脑血管病杂志, 2005, 7(3): 192-194. Su Xin, Zhang Wenzhi, Wu Jianjuan. Effect of amyloid-β protein on cultured neural stem cells of fetal rat[J]. Chinese Journal of Geriatric Heart Brain and Vessel Diseases, 2005, 7(3): 192-194.
[26] Nelson T J, Alkon D L. Oxidation of cholesterol by amyloid precursor protein and β- amyloid peptide[J]. Journal of Biological Chemistry, 2005, 280(8): 7377-7387.
[27] Hashimoto M, Rockenstein E, Crews L, et al. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's disease[J]. Neuromolecular Medicine, 2003, 4(1-2): 21-36.
[28] Renolleau S, Aggoun Z D, Ben A Y, et al. A model of transient unilateral focal ischemia with reperfusion in the P7 neonatal rat: Morphological changes indicative of apoptosis[J]. Stroke, 1998, 29(7): 1454-1461.
[29] Gervais F G, Xu D, Robert son G S, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid- beta precursor protein and amyloidogenic A beta peptide formation[J]. Cell, 1999, 97(4): 395-406.
[30] Lee P H, Hwang E M. Effect of ischemic neuronal insults on amyloid precursor protein processing[J]. Neurochemitry Research, 2006, 31: 821-827.
[31] Perluigi M, Joshi G, Sultana R. In vivo protection by the xanthate tricyclodecan-9-yl-xanthogenate against amyloid beta-peptide(1-42)- induced oxidative stress[J]. Neuroscience, 2006, 138(4): 1161-1170.
[32] Watanabe T, Tahara M, Todo S. The novel antioxidant edaravone: From bench to bedside[J]. Cardiovascular Therapeutics, 2008, 26: 101-114.
[33] Yoshida H, Yanai H, Namiki Y, et al. Neuroprotective effects of edaravone: A novel free radical scavenger in cerebrovascular injury[J]. CNS Drug Reviews, 2006, 12: 9-20.
[34] Takamatsu Y, Yuki S, Watanabe T. Studies on the concentration of 3- methyl-1-phenyl-2-pyrazolin-5-one(MCI-186) in MCA occlusion and reperfusion model of rats[J]. Japan Pharmacology Therapeutics, 1997, 25(Supp l): S1785-S1791.
[35] Yang J, Cui X, Li J, et al. Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials[J]. Developmental Neurorehabilitation, 2013, doi: 10.3109/17518423.2013.830153.
[36] Xiao B, Bi F F, Hu Y Q. Edaravone neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats[J]. Neurotoxicity Research, 2007, 12 (3): 155-162.

Options

文章导航

摘要

本文引用格式

Abstract

参考文献

联系我们

访问统计

模态框（Modal）标题

摘要

本文引用格式

Abstract

参考文献

联系我们

访问统计